Aerpio Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aerpio Pharmaceuticals generated cash of -$32,481,000, which is less than the previous year. Cash used in financing activities reached the amount of $44,016,000 last year. Net change in cash is therefore $9,324,000.
Cash Flow
| 2011 | -19.24K | 0 | 35K |
|---|---|---|---|
| 2017 | -13.84M | -2.45M | 28.57M |
| 2018 | -10.62M | 8.81M | 0 |
| 2019 | -15.58M | 2.87M | 8.97M |
| 2020 | -18.27M | -824K | 23.21M |
| 2021 | -23.57M | -1.30M | 25.51M |
| 2022 | -32.48M | -2.21M | 44.01M |
ARPO Cash Flow Statement (2011 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2011 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 11.48M | 10.84M | 6.73M | 10.46M | 12.27M | 0 | -11.63K |
Operating activities | |||||||
Net income | -36.91M | -23.15M | -22.18M | -19.47M | -16.70M | -15.12M | -22.39K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 892K | 1.16M | 1.11M | 1.35M | 1.35M | 1.53M | 0 |
Stock-based compensation expense | 3.10M | 2.88M | 3.47M | 4.27M | 46K | 273K | 0 |
| Deferred income tax benefit | 3.10M | 2.88M | 3.47M | 4.27M | 46K | 273K | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 1.89K |
Cash generated by operating activities | -32.48M | -23.57M | -18.27M | -15.58M | -10.62M | -13.84M | -19.24K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -2.21M | -1.30M | -824K | -224K | -875K | -546K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -2.21M | -1.30M | -824K | 2.87M | 8.81M | -2.45M | 0 |
Financing activities | |||||||
Common Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -4.12K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 44.01M | 25.51M | 23.21M | 8.97M | 0 | 28.57M | 35K |
Net Change In Cash | 9.32M | 639K | 4.11M | -3.73M | -1.81M | 12.27M | 15.75K |
Cash at end of period | 20.81M | 11.48M | 10.84M | 6.73M | 10.46M | 12.27M | 4.12K |
| Data source |